Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of type 2 diabetes~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Either failed treatment with diet and exercise for 3 months prior to Screening or has been receiving a stable dose of metformin, sulfonylurea, nateglinide, or repaglinide for more than 3 months prior to Screening.~* Inadequate glycemic control as defined by glycosylated hemoglobin concentration between 6.5 and 9.0%, inclusive.~* Fasting plasma glucose less than 13.3 mmol per L.~* Fasting serum triglyceride level of 1.7 to 5.0 mmol per L, inclusive.~* Has not been receiving any lipid-lowering therapy within 3 months prior to Screening or on a stable statin and/or ezetimibe therapy (same drug and dose) for at least 3 months.~* Body mass index greater than 23 kg/m2 and less than 45 kg/m2.~* If has regular use of other, non-excluded medications, must be on a stable dose for at least 4 weeks prior to Screening. Use of as needed prescription medications and over-the-counter medications is allowed at the discretion of the investigator.~* Is to be Apolipoprotein E 3/3 or Apolipoprotein E 3/4 phenotype positive prior to baseline.~Exclusion Criteria~* History of type 1 diabetes.~* History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.~* Diastolic blood pressure greater than 100 mm Hg or a systolic blood pressure of greater than 160 mm Hg.~* History of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study medication.~* Hemoglobin less than 120 g per L for males and less than100 g per L for females.~* Alanine transaminase level greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.~* Serum creatinine level greater than 133 μmol per L.~* Fasting total cholesterol greater than 6.5 mmol per L.~* New York Heart Association heart failure of any Class (I-IV) regardless of therapy.~* History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.~* History of acute metabolic diabetic complications.~* History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.~* History of infection with human immunodeficiency virus.~* History of diabetic gastro paresis.~* History of gastric bypass surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo QD (Type: PLACEBO_COMPARATOR): None
- Alogliptin 25 mg QD (Type: EXPERIMENTAL): None
- Alogliptin 25 mg QD + Pioglitazone 30 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).